|Publication Type||Journal Article|
|Year of Publication||2009|
|Authors||Kuhn, E, Addona, T, Keshishian, H, Burgess, M, Mani, DR, Lee, RT, Sabatine, MS, Gerszten, RE, Carr, SA|
Protein biomarker candidates from discovery proteomics must be quantitatively verified in patient samples before they can progress to clinical validation. Here we demonstrate that peptide immunoaffinity enrichment coupled with stable isotope dilution mass spectrometry (SISCAPA-MRM) can be used to configure assays with performance suitable for candidate biomarker verification. As proof of principle, we configured SISCAPA assays for troponin I (cTnI), an established biomarker of cardiac injury, and interleukin 33 (IL-33), an emerging immunological and cardiovascular marker for which robust immunoassays are currently not available.